TEM Tempus AI Inc

$TEM only good news 1.Personalis-Tempus merger clears key regulatory milestone 2.Partnership extended for 7 years with Merck and Moderna What else do we need to move this back? Souls be a GREEN DAY.

$TEM $MRNA $MRK TEM Tempus Announces Multi-Year Collaboration with Moderna and Merck "oday announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene (V940/mRNA-4157), a novel, potential first-in-class individualized neoantigen therapy (INT) being evaluated in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with completely resected stage IIB-IV melanoma and other cancer types. Intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada. The collaboration builds on joint efforts initiated last year and will support preparations for the potential commercialization of intismeran autogene."

$TEM The fundamental story backs the chart: pharma data deals are stacking up, margins are improving, and guidance was raised last quarter. The risk is the calendar. You’d be buying a momentum breakout four trading days before a report where the stock has sold off four straight times, even on beats. One way to play it is a partial position now and adding after Monday’s reaction.

$TEM Looking to Swing trade from this area. Will continue to accurate shares till close. ✊🏿

$TEM bullish trend still intact. Sitting at lower trend line. Looking for a bounce here

$TEM probably sweeps down to 60 then gives you the ramp back holding the psychological level and running stops. Low risk spot at 60-61 vs 56. Below and it’s pretty ugly.

$TEM So unfair. Rich people buy, sell, buy again, rinse and repeat makes billion. At this point, I kind of like the CCP Iran Russia. Fml

$TEM 💥💯💰💰💰💰💰💯💥 EXTREMELY BULLISH SETUP! Double-bottom support near $66.85 is holding strong, price reclaimed both converging EMAs, RSI surged from 16.7 to 53.7, and MACD flipped bullish with an expanding positive histogram. Momentum is shifting decisively toward the bulls, setting the stage for a potential breakout and powerful squeeze!💥🚀💰🏆

$TEM 💥💯🚀💥💯🚀💥💯🚀💥💯🚀 The oversold bounce is forming & RSI is curling out! Time for a nice bounce & accumulation time.

$TEM Looking forward to this week. Hopefully we can make some moves up to 75, then 85 after.

$TEM Daddys average in Tempus shares is now 51 $ after the add at 69$. Holding this probably into the 2030s. Swing trading with puts once this board gets excited again. Not yet.

$TEM wow what a close great big buys end of day ! You are holding a lot of gold TEM ers !

$TEM bought 1000 shares at $73.80. Will continue to buy if it keeps going lower and dollar cost average. Why try to catch a bottom

$TEM Here is my analysis: today will close at about 72ish, tomorrow the range will be 73 to 70ish, and Thursday it might go to 78ish.

$TEM sold before close. Not holding through earnings Nov 2nd, looking for a drop in the low $60. Every earning announcement has been a sell the news event. Let the dust settle..

$TEM if Tempus went up 4x it would still be smaller than Natera, so much more room to run

$TEM AMAZING MORE GREAT NEWS TEMPUS AI (TEM): MAJOR EUROPEAN MILESTONE! Tempus AI has received EU IVDR Class C certification for its xR RNA sequencing assay, strengthening its position in cancer diagnostics and expanding its commercial opportunities across Europe. THE REVENUE OPPORTUNITY: European market expansion, increased cancer testing, and additional pharmaceutical partnerships could create significant new revenue opportunities for Tempus. Another important achievement as Tempus AI prepares to report Q3 earnings on November 2!

$TEM Tempus AI shares are trading higher after the company announced a multi-year agreement with Bristol Myers Squibb, under which BMS will license multimodal oncology data from Tempus through 2031.

$TEM 🚨💥💰🚨💥💰🪎 Tempus's new ESMO data is a strong validation point. Across 60,459 advanced NSCLC cases, its H&E-based panel hit greater than 80% sensitivity on all 12 biomarkers and above 90% on several. That is a large, multi-center dataset, which is hard for competitors to replicate. Why it matters: • Real clinical pain point: NSCLC testing often needs multiple tests and enough tissue. A tool that triages testing from slides already in hand speeds results and conserves samples. • Pharma validation: The work came out of the Pfizer collaboration. It also follows the expanded Moderna/Merck deal announced earlier this month. • Compounding data moat: It builds on Paige Predict (123 biomarkers) and Tempus Preview (predictions about 24 hours after sample receipt). Each new use case makes the data library more valuable. • Near-term catalyst: Q3 results come on November 2, and 13 abstracts will be shown at ESMO on October 23–27.

$TEM Not too worried. Just general macros after the attacks this weekend on the Saudi airport.